Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies
(mAbs) can unleash antitumor functions of T cells but is associated with variable response …

Photodynamic therapy (PDT) is a clinically approved cancer therapy, based on a
photochemical reaction between a light activatable molecule or photosensitizer, light, and …

Nanotechnology offers several attractive design features that have prompted its exploration
for cancer diagnosis and treatment. Nanosized drugs have a large loading capacity, the …

Antibody-drug conjugates (ADCs) are complex engineered therapeutics consisting of
monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent …

Nanocarriers have been widely employed in preclinical studies and clinical trials for the
delivery of anticancer drugs. The most important causes of failure in clinical translation of …

The interface of bio–nano science and cancer medicine is an area experiencing much
progress but also beset with controversy. Core concepts of the field eg, the enhanced …

As medicine progresses into a new era of personalised therapy, the use of monoclonal
antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the …